Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MajesTEC-7 in transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma
jRCT2031240014Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised trial of teclistamab, talquetamab, daratumumab, lenalidomide and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Progression-free survival, 12-month MRD-negative complete response and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
teclistamabtalquetamabdaratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031240014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240014.